ITEMS IN AFP WITH KEYWORD:

Diabetes

Aug 1, 2016 Issue
Treating Painful Diabetic Peripheral Neuropathy: An Update [Article]

Painful diabetic neuropathic pain causes patients to experience burning pain, paresthesias, and numbness that progress from the feet and hands to the rest of the body. Although several therapeutic modalities are available for its treatment, many patients do not receive adequate care.


Jul 1, 2016 Issue
Blood Pressure Goal of 140 to 150 mm Hg Is Best for Patients with Diabetes [POEMs]

Although most recent practice guidelines have relaxed the blood pressure goals for patients with diabetes, there are still a few holdouts that suggest aggressive treatment. This analysis shows that the ideal range for hypertension control in patients with diabetes is between 140 and 150 mm Hg; highe...


Jun 15, 2016 Issue
Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus [Putting Prevention into Practice]

M.A. is a 43-year-old woman with a seven pack-year smoking history. She has no health concerns and has not visited a physician in four years. Her blood pressure and pulse are normal, and her body mass index (BMI) is 27 kg per m2. She does not have a family history of diabetes mellitus but notes that...


May 1, 2016 Issue
Alpha-Lipoic Acid for Treatment of Diabetic Peripheral Neuropathy [FPIN's Help Desk Answers]

Intravenous (IV) ALA can improve neuropathy symptoms when administered for three weeks, but symptom improvement with oral ALA is not clinically significant. There is no evidence evaluating long-term treatment.


Mar 15, 2016 Issue
Systolic BP of 120 Instead of 140 in High-Risk Older Patients Without Diabetes Leads to Significant Benefits and Some Harms [POEMs]

In this group of older patients (mean age = 68 years) who do not have diabetes but are at high risk of cardiovascular disease, a more aggressive systolic BP target of 120 mm Hg instead of 140 mm Hg led to benefits (lower all-cause mortality, lower cardiovascular mortality, less heart failure), but a...


Mar 1, 2016 Issue
In Patients with Type 2 Diabetes and CV Disease, Empagliflozin Reduces CV and All-Cause Mortality [POEMs]

In patients with established CV disease and type 2 diabetes, the addition of empagliflozin to standard therapy reduces all-cause mortality and CV mortality. This is notable because empagliflozin is the only drug other than metformin to demonstrate a mortality benefit, albeit for a fairly narrow group of patients.


Feb 1, 2016 Issue
Preventing CVD in Adults with Type 2 Diabetes Mellitus: An Update from the AHA and ADA [Practice Guidelines]

The American Heart Association (AHA) and American Diabetes Association (ADA) joined together to release statements on preventing CVD in persons with diabetes.


Jan 15, 2016 Issue
Diabetes Mellitus: Screening and Diagnosis [Article]

Review key screening recommendations for type 2 diabetes in nonpregnant adults, pregnant women, children, and older persons. Learn which test results are considered diagnostic.


Jan 15, 2016 Issue
Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: Recommendation Statement [U.S. Preventive Services Task Force]

The USPSTF recommends screening for abnormal blood glucose as part of cardiovascular risk assessment in adults aged 40 to 70 years who are overweight or obese. Clinicians should offer or refer patients with abnormal blood glucose to intensive behavioral counseling interventions to promote a healthful diet and physical activity.


Dec 1, 2015 Issue
Adding Sitagliptin Does Not Reduce or Increase the Risk of Cardiovascular Outcomes [POEMs]

The glass half full is that sitagliptin does not increase the risk of cardiovascular events in patients with type 2 diabetes. The glass half empty is that it does not reduce the risk, either. And that is the important message: In patients with a mean glycated hemoglobin level of 7.2%, adding sitagli...


Pages: Previous 1 2 3 4 5 6 7 8 9 10 ... 15 Next


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now